X

DBL VINBLASTINE INJECTION

Product Information

Registration Status: Active

SIN07944P

DBL VINBLASTINE INJECTION is approved to be sold in Singapore with effective from 1994-09-12. It is marketed by HOSPIRA SINGAPORE PTE LTD, with the registration number of SIN07944P.

This product contains Vinblastine 1mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.

This product is manufactured by HOSPIRA AUSTRALIA PTY LTD in AUSTRALIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Mechanism of Action

The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.

Toxicity

Oral, mouse: LD50 = 423 mg/kg; Oral, rat: LD50 = 305 mg/kg.

Active Ingredient/Synonyms

Vinblastin | Vinblastina | Vinblastine | Vinblastinum | Vincaleukoblastine | Vinblastine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!